ES2163531T3 - Carboxilatos de aminoguanidina para el tratamiento de diabetes mellitus no insulinodependiente. - Google Patents

Carboxilatos de aminoguanidina para el tratamiento de diabetes mellitus no insulinodependiente.

Info

Publication number
ES2163531T3
ES2163531T3 ES95939672T ES95939672T ES2163531T3 ES 2163531 T3 ES2163531 T3 ES 2163531T3 ES 95939672 T ES95939672 T ES 95939672T ES 95939672 T ES95939672 T ES 95939672T ES 2163531 T3 ES2163531 T3 ES 2163531T3
Authority
ES
Spain
Prior art keywords
treatment
insulined
nell
independent diabetes
aminoguanidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95939672T
Other languages
English (en)
Inventor
Scott D Larsen
Valerie A Vaillancourt
Paul D May
Steven P Tanis
John A Tucker
Martin D Meglasson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swedish Orphan Biovitrum AB
Original Assignee
Biovitrum AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/484,547 external-priority patent/US5994577A/en
Application filed by Biovitrum AB filed Critical Biovitrum AB
Application granted granted Critical
Publication of ES2163531T3 publication Critical patent/ES2163531T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/16—Compounds containing any of the groups, e.g. aminoguanidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/16—Compounds containing any of the groups, e.g. aminoguanidine
    • C07C281/18—Compounds containing any of the groups, e.g. aminoguanidine the other nitrogen atom being further doubly-bound to a carbon atom, e.g. guanylhydrazones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCION, PROPORCIONA NUEVOS COMPUESTOS DE FORMULAS (I): AG-(CH{SUB,2}){SUB,N}-CO{SUB,2}R{SUP,1} Y (II) O LAS SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS, DONDE AG ES : A) N-AMINOGUANIDINA, B) N,N''-DIAMINOGUANIDINA, O C) N,N'',N''''-TRIAMINOGUANIDINA; Y EL SIGNIFICADO DE N, R{SUP,1} Y R{SUP,2}, SE INDICA EN LA DESCRIPCION. SE PRESENTA ASIMISMO, UNA NUEVA UTILIZACION DE LOS COMPUESTOS DE FORMULA (III), DONDE R{SUP,3} TIENE LOS SIGNIFICADOS INDICADOS EN LA DESCRIPCION, PARA EL TRATAMIENTO DE LA DIABETES MELLITUS NO DEPENDIENTE DE INSULINA (NIDDM).
ES95939672T 1994-11-23 1995-11-13 Carboxilatos de aminoguanidina para el tratamiento de diabetes mellitus no insulinodependiente. Expired - Lifetime ES2163531T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34427494A 1994-11-23 1994-11-23
US08/484,547 US5994577A (en) 1994-11-23 1995-06-07 Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus

Publications (1)

Publication Number Publication Date
ES2163531T3 true ES2163531T3 (es) 2002-02-01

Family

ID=26993832

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95939672T Expired - Lifetime ES2163531T3 (es) 1994-11-23 1995-11-13 Carboxilatos de aminoguanidina para el tratamiento de diabetes mellitus no insulinodependiente.

Country Status (24)

Country Link
US (2) US6166080A (es)
EP (1) EP0793646B1 (es)
JP (1) JPH10509455A (es)
CN (2) CN1097580C (es)
AT (1) ATE205188T1 (es)
AU (1) AU705893B2 (es)
BR (1) BR9509741A (es)
CA (1) CA2202265A1 (es)
CZ (1) CZ288597B6 (es)
DE (2) DE793646T1 (es)
DK (1) DK0793646T3 (es)
EE (1) EE03392B1 (es)
ES (1) ES2163531T3 (es)
FI (1) FI972185A0 (es)
GE (1) GEP20002026B (es)
HU (1) HUT77133A (es)
MX (1) MX9703807A (es)
NO (1) NO308992B1 (es)
NZ (1) NZ297604A (es)
PL (1) PL184614B1 (es)
PT (1) PT793646E (es)
RU (1) RU2162462C2 (es)
SK (1) SK282357B6 (es)
WO (1) WO1996016031A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9526331D0 (en) * 1995-12-22 1996-02-21 Smithkline Beecham Plc Novel method
EP0912523A1 (en) * 1996-05-21 1999-05-06 PHARMACIA & UPJOHN COMPANY Aminoguanidine carboxylate lactams for the treatment of non-insulin-dependent diabetes mellitus
JP2001512450A (ja) * 1997-02-13 2001-08-21 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 糖尿病治療のための一酸化窒素シンターゼ阻害剤の使用
US6001578A (en) * 1997-06-26 1999-12-14 Pharmacia & Upjohn Ab Methods of screening for modulators of uncoupling protein-2 (UCP-2) as potential treatments for obesity
SE9702457D0 (sv) * 1997-06-26 1997-06-26 Pharmacia & Upjohn Ab Screening
US6288124B1 (en) 1998-05-22 2001-09-11 Rima Kaddurah-Daouk Methods of inhibiting undesirable cell growth using an aminoguanidine compound
US6169115B1 (en) 1998-05-22 2001-01-02 Rima Kaddurah-Daouk Use of aminoguanidine analogs for the treatment of diseases of the nervous system
US6815421B1 (en) * 2001-03-22 2004-11-09 Osteopharm Inc. Polypeptides for use in ameliorating effects of aging in mammals
US8871527B2 (en) * 2008-04-29 2014-10-28 Becton, Dickinson And Company Method and system for measuring a sample to determine the presence of and optionally treat a pathologic condition
PL2303838T3 (pl) * 2008-06-26 2014-07-31 Laboratorios Silanes S A De C V Nowa sól glicynianowa metforminy do kontroli glukozy we krwi
GB201300435D0 (en) * 2013-01-10 2013-02-27 Medical Res Council Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases
JP6121638B2 (ja) * 2015-04-23 2017-04-26 三菱瓦斯化学株式会社 ガス発生剤、及びそれを用いた発泡体の製造方法
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
WO2018160178A1 (en) 2017-03-01 2018-09-07 Rgenix, Inc. Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof
IL293721A (en) 2019-12-11 2022-08-01 Inspirna Inc Cancer treatment methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3412105A (en) 1966-01-05 1968-11-19 American Home Prod beta-aryl-n-guanidino-beta-alanines
US3943253A (en) * 1974-06-27 1976-03-09 Barer Sol J Guanido acids as fungicides
JPS54128523A (en) 1978-03-29 1979-10-05 Nippon Carbide Ind Co Ltd 3-guanidinoamino propionic acid and its preparation
US4758583A (en) * 1984-03-19 1988-07-19 The Rockefeller University Method and agents for inhibiting protein aging
US5272165A (en) * 1984-03-19 1993-12-21 The Rockefeller University 2-alkylidene-aminoguanidines and methods of use therefor
US5130324A (en) * 1984-03-19 1992-07-14 The Rockefeller University 2-alkylidene-aminoguanidines and methods of use therefor
IT1201511B (it) 1985-12-23 1989-02-02 Italfarmaco Spa Derivati citoprotettivi in patologie a base ischemica,loro preparazione e composizioni che li cntengono
US5059712A (en) 1989-09-13 1991-10-22 Cornell Research Foundation, Inc. Isolating aminoarginine and use to block nitric oxide formation in body
GB9200114D0 (en) 1992-01-04 1992-02-26 Scras Dual inhibitors of no synthase and cyclooxygenase

Also Published As

Publication number Publication date
CZ288597B6 (cs) 2001-07-11
BR9509741A (pt) 1997-10-21
CZ136997A3 (cs) 1998-02-18
NO972346L (no) 1997-07-23
EP0793646B1 (en) 2001-09-05
HUT77133A (hu) 1998-03-02
JPH10509455A (ja) 1998-09-14
DE69522580T2 (de) 2002-10-10
SK282357B6 (sk) 2002-01-07
SK64097A3 (en) 1997-11-05
US6166080A (en) 2000-12-26
CA2202265A1 (en) 1996-05-30
MX9703807A (es) 1997-08-30
GEP20002026B (en) 2000-04-10
AU4279696A (en) 1996-06-17
PL184614B1 (pl) 2002-11-29
DE793646T1 (de) 1999-12-30
FI972185A (fi) 1997-05-22
FI972185A0 (fi) 1997-05-22
DE69522580D1 (de) 2001-10-11
NO972346D0 (no) 1997-05-22
EE03392B1 (et) 2001-04-16
DK0793646T3 (da) 2001-12-17
EE9700094A (et) 1997-10-15
CN1164226A (zh) 1997-11-05
EP0793646A1 (en) 1997-09-10
AU705893B2 (en) 1999-06-03
ATE205188T1 (de) 2001-09-15
PL320361A1 (en) 1997-09-29
US6329545B1 (en) 2001-12-11
CN1377642A (zh) 2002-11-06
PT793646E (pt) 2002-03-28
NO308992B1 (no) 2000-11-27
RU2162462C2 (ru) 2001-01-27
NZ297604A (en) 2000-07-28
CN1097580C (zh) 2003-01-01
WO1996016031A1 (en) 1996-05-30

Similar Documents

Publication Publication Date Title
ES2163531T3 (es) Carboxilatos de aminoguanidina para el tratamiento de diabetes mellitus no insulinodependiente.
DE69519207T2 (de) Kautschukzusammensetzung ohne Gehalt an carcinogenen Nitrosaminvorläufern, die als Verbindungsgummi geeignet ist
GB9514473D0 (en) Chemical compounds
MX9704377A (es) Uso de pramipexole como agente neuroprotector.
PT687260E (pt) Processo para a preparacao de 9-desoxotaxanos
EP0330041A3 (de) Substituierte 1,2,4-Triazindione, Verfahren zu ihrer Herstellung und ihre Verwendung
AU5699494A (en) Novel liquid phenolic antioxidants
PT722319E (pt) Derivados de antraciclinona e a sua utilizacao no tratamento da amiloidose
FI951511A (fi) IL-10:n käyttö insuliinista riippuvan diabetes mellituksen ennaltaestoon tai hoitoon
DE69510545T2 (de) Cck oder gastrin modulierende 5-heterocyclicyl-1,5-benzodiazepine
NO965233L (no) Deacetoksytaksolderivater
DE69108358D1 (de) Heptamethyl-Indanverbindung.
AU648285B2 (en) Coating material, process for producing it and its use
IL158356A0 (en) Benzoheterocycles
EP0566666A4 (en) Novel glucohydrolase inhibitors useful as antidiabetic agents
ES2084733T3 (es) Nuevos substratos de beta-galactosidasa para el analisis cedia.
FI943797A (fi) Virusvastaiset tiatsolit
ES2074250T3 (es) Azocolorantes, procedimiento para su preparacion y su empleo.
ES2175228T3 (es) Metilsulfomicina i, un procedimiento para su produccion y su uso.
ES2185154T3 (es) Metodo de uso de inhibidores de la ciclooxigenasa-2 en el tratamiento y prevencion de la demencia.
ES2085074T3 (es) Cloroetilsulfonilbenzaldehidos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 793646

Country of ref document: ES